Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 13/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30848075 | 1.00 | CYP2C9 (0.33) | CYP2C9NR1H2NR1H3SCN9AHDAC4 | |
| SCHEMBL27143429 | 0.87 | CYP17A1 (0.38) | SCN9ASCN2ASCN5A | |
| SCHEMBL30847891 | 0.87 | CYP17A1 (0.38) | SCN9ASCN2ASCN5A | |
| SCHEMBL30847936 | 0.86 | CYP17A1 (0.38) | SCN9ASCN2ASCN5A | |
| SCHEMBL27143717 | 0.86 | CYP17A1 (0.38) | SCN9ASCN2ASCN5A | |
| SCHEMBL30846477 | 0.85 | GAA (0.37) | SCN9AHDAC4SCN2ASCN5A | |
| SCHEMBL27121225 | 0.85 | GAA (0.37) | SCN9AHDAC4SCN2ASCN5A | |
| SCHEMBL30847973 | 0.85 | SLC34A1 (0.35) | — | |
| SCHEMBL27132483 | 0.85 | SLC34A1 (0.35) | — | |
| SCHEMBL30847843 | 0.84 | SLC40A1 (0.36) | SCN9ASCN2ASCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| WO-2024044730-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | HOTSPOT THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150321-A1 | PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY | MALT1, BCL6, BCL3 | CYP2C9 3468/4885NR1H2 2807/4885NR1H3 2620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.